BioToxTech Co

BioToxTech Co OCF/Debt

The Operating Cash Flow to Debt Ratio of BioToxTech Co (086040.KQ) as of Oct 20, 2026 is 58.99 %. In the previous year, Operating Cash Flow to Debt Ratio was -18.49 % — a change of -419.03% (higher).

OCF/Debt

58.99 %

YoY

-419.03%

Last updated:

Operating Cash Flow to Debt Ratio of BioToxTech Co is 2025 58.99 % . Operating Cash Flow to Debt Ratio of BioToxTech Co was 2024 -18.49 % . It decreases by -419.03% higher compared to the previous year.

The BioToxTech Co OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2018
18.26 KRW
Jan 1, 2019
8.69 KRW
Jan 1, 2020
37.00 KRW
Jan 1, 2021
28.32 KRW
Jan 1, 2022
-3.80 KRW
Jan 1, 2023
-36.88 KRW
Jan 1, 2024
-18.49 KRW
Jan 1, 2025
58.99 KRW
The BioToxTech Co OCF/Debt history
YEAROCF/DebtYoY
58.99 %-419.03%
-18.49 %-49.87%
-36.88 %+871.69%
-3.80 %-113.41%
28.32 %-23.48%
37.00 %+325.80%
8.69 %-52.41%
18.26 %-53.63%
39.38 %+0.55%
39.17 %-792.32%
-5.66 %-93.09%
-81.90 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Operating Cash Flow to Debt Ratio of BioToxTech Co is 58.99 % in 2025.

Operating Cash Flow to Debt Ratio of BioToxTech Co changed from -18.49 % to 58.99 %, representing a -419.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's BioToxTech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BioToxTech Co

All Key Metrics — BioToxTech Co